Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Takumi Fukumoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1592-4524; OpenAlex author ID A5019139994, A5056118777, A5109288556. Sources: OpenAlex.

Their work

Papers
51 (first author 0, last author 16)
Trials
0
Grants
0
Labs led
1
Collaborators
83
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 2 papers · 2014: 1 paper · 2015: 5 papers · 2016: 4 papers · 2017: 4 papers · 2018: 3 papers · 2019: 4 papers · 2020: 1 paper · 2021: 3 papers · 2022: 4 papers · 2023: 7 papers · 2024: 3 papers · 2025: 1 paper · 2026: 7 papers

Papers 50 of 51

  1. Learning Curve Effect in Reducing Local Recurrence Rate After Resection of Pancreatic Cancer With Arterial Abutment: A Single-Center Retrospective Study. Last author DOI 10.1002/ags3.70100↗
  2. Proton Radiotherapy with Induction Chemotherapy for Locally Advanced Pancreatic Cancer: A Retrospective Analysis of Treatment Strategy and Outcomes. Co-author DOI 10.1016/j.clon.2026.104204↗
  3. Intraoperative frozen section analysis of the portal or superior mesenteric vein transection margin in pancreatectomy with venous resection for pancreatic canc… Last author DOI 10.1016/j.gassur.2026.102410↗
  4. Biological Borderline Resectable Pancreatic Cancer Represents a Genetically and Immunologically Aggressive Subtype: A Retrospective Study. Co-author DOI 10.1097/sla.0000000000007075↗
  5. Short- and Long-Term Outcomes after Pancreatectomy for Pancreatic Cancer in Patients with Prior Esophagectomy for Esophageal Cancer. Last author DOI 10.1245/s10434-025-18491-3↗
  6. ASO Visual Abstract: Short- and Long-Term Outcomes after Pancreatectomy for Pancreatic Cancer in Patients with Prior Esophagectomy for Esophageal Cancer. Last author DOI 10.1245/s10434-025-18718-3↗
  7. Delayed Initiation of S-1 Adjuvant Chemotherapy Impairs Survival in Patients With Curatively Resected Pancreatic Cancer. Last author DOI 10.21873/anticanres.18004↗
  8. Prognostic Significance of GLIM-Defined Malnutrition in Patients With Resectable Pancreatic Adenocarcinoma Following Upfront Surgery. Last author DOI 10.1002/ags3.70059↗
  9. Impact of intratumoral microbiome on tumor immunity and prognosis in human pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-023-02069-5↗
  10. Preoperative level of serum transthyretin as a novel biomarker predicting survival in resected pancreatic ductal adenocarcinoma with neoadjuvant therapy. Last author DOI 10.1016/j.pan.2024.07.012↗
  11. Treatment and Prognosis for Pancreatic Duct Disruption Associated With Pancreatic Cancer: A Case Series of 15 Patients. Co-author DOI 10.7759/cureus.67482↗
  12. Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-022-01939-8↗
  13. A comprehensive analysis of tumor-stromal collagen in relation to pathological, molecular, and immune characteristics and patient survival in pancreatic ductal… Co-author DOI 10.1007/s00535-023-02020-8↗
  14. A case of pancreatic ductal adenocarcinoma concomitant with IgG4-related disease in the pancreas and the stomach. Co-author DOI 10.1007/s12328-023-01814-w↗
  15. Clinicopathological variables and risk factors for lung recurrence after resection of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.asjsur.2022.03.043↗
  16. Benefits of pancreatic parenchymal endoscopic ultrasonography in predicting microscopic precancerous lesions of pancreatic cancer. Co-author DOI 10.1038/s41598-023-38920-1↗
  17. Proton radiotherapy as a treatment strategy to increase survival in locally advanced pancreatic cancer in the body and tail: a retrospective study. Last author DOI 10.1186/s13014-023-02301-9↗
  18. Association of Sarcopenia with a Poor Prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in Pancreatic Ductal Adenocarcinoma: A Retrospective Anal… Co-author DOI 10.1245/s10434-023-13569-2↗
  19. Abbreviated Gadoxetic Acid-Enhanced MRI for the Detection of Liver Metastases in Patients With Potentially Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/jmri.28059↗
  20. Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center… Last author DOI 10.1186/s13014-022-02001-w↗
  21. Comprehensive Analysis of Molecular Biologic Characteristics of Pancreatic Ductal Adenocarcinoma Concomitant with Intraductal Papillary Mucinous Neoplasm. Co-author DOI 10.1245/s10434-022-11704-z↗
  22. Increased expression of SPRR1A is associated with a poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0266620↗
  23. Efficacy of Spacers in Radiation Therapy for Locally Advanced Pancreatic Cancer: A Planning Study. Co-author DOI 10.21873/anticanres.14801↗
  24. [A Patient with Ascending Jejunal Mesentery Metastasis of Pancreatic Cancer after a Subtotal Stomach-Preserving Pancreaticoduodenectomy]. Last author PMID 35045476↗
  25. [A Case of Pancreatic Cancer with Gastric Wall Recurrence after Laparoscopic Distal Pancreatectomy Due to Needle Tract Seeding following EUS-FNA]. Last author PMID 35045477↗
  26. Response to: "timing of administration of indocyanine green for fluorescence-guided surgery in pancreatic cancer: response to Shirakawa et al." Last author DOI 10.1186/s12893-020-00815-7↗
  27. Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively … Co-author DOI 10.1007/s00268-018-4814-4↗
  28. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicente… Co-author DOI 10.1186/s12885-019-5460-4↗
  29. A prospective single-center protocol for using near-infrared fluorescence imaging with indocyanine green during staging laparoscopy to detect small metastasis … Last author DOI 10.1186/s12893-019-0635-0↗
  30. Proton Radiotherapy for Isolated Local Recurrence of Primary Resected Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-019-07471-z↗
  31. Pancreatic inflammation and atrophy are not associated with pancreatic cancer concomitant with intraductal papillary mucinous neoplasm. Co-author DOI 10.1016/j.pan.2017.12.007↗
  32. Multifocal cysts and incidence of pancreatic cancer concomitant with intraductal papillary mucinous neoplasm. Co-author DOI 10.1016/j.pan.2018.04.005↗
  33. Pathological and Radiological Splenic Vein Involvement are Predictors of Poor Prognosis and Early Liver Metastasis After Surgery in Patients with Pancreatic Ad… Last author DOI 10.1245/s10434-017-6274-8↗
  34. Retrospective Study of the Correlation Between Pathological Tumor Size and Survival After Curative Resection of T3 Pancreatic Adenocarcinoma: Proposal for Recl… Co-author DOI 10.1007/s00268-017-4077-5↗
  35. Smoking Status and the Incidence of Pancreatic Cancer Concomitant With Intraductal Papillary Mucinous Neoplasm. Co-author DOI 10.1097/mpa.0000000000000761↗
  36. Pancreatic ductal adenocarcinoma with inferior vena cava invasion: a report of three resected cases. Co-author DOI 10.1186/s40792-017-0348-5↗
  37. [A Case of Pancreatic Cancer with Multiple Lymph Node Swelling Caused by Sarcoidosis]. Co-author PMID 29394809↗
  38. Prognosis after surgical treatment for pancreatic cancer in patients aged 80 years or older: a multicenter study. Co-author DOI 10.1002/jhbp.320↗
  39. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophi… Co-author DOI 10.1007/s00595-015-1206-3↗
  40. Grade B pancreatic fistulas do not affect survival after pancreatectomy for pancreatic cancer: A multicenter observational study. Co-author DOI 10.1016/j.surg.2016.02.032↗
  41. Reappraisal of Total Pancreatectomy in 45 Patients With Pancreatic Ductal Adenocarcinoma in the Modern Era Using Matched-Pairs Analysis: Multicenter Study Grou… Co-author DOI 10.1097/mpa.0000000000000579↗
  42. Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients. Co-author DOI 10.1007/s00535-014-1005-4↗
  43. Reappraisal of peritoneal washing cytology in 984 patients with pancreatic ductal adenocarcinoma who underwent margin-negative resection. Co-author DOI 10.1007/s11605-014-2637-7↗
  44. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center r… Co-author DOI 10.1016/j.pan.2015.09.008↗
  45. Postoperative Serum Albumin Level is a Marker of Incomplete Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-014-4280-7↗
  46. Impact of Preoperative Biliary Drainage on Long-Term Survival in Resected Pancreatic Ductal Adenocarcinoma: A Multicenter Observational Study. Co-author DOI 10.1245/s10434-015-4618-9↗
  47. [A case of adjuvant surgery for a patient with initially unresectable locally advanced pancreatic cancer (LAPC) with a favorable response to S-1 chemotherapy]. Co-author PMID 25731462↗
  48. 18-Fluorodeoxyglucose positron emission tomography does not aid in diagnosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.cgh.2012.12.033↗
  49. [A case of metachronous pancreatic cancer that developed 4 years after initial pancreatectomy]. Co-author PMID 24393957↗
  50. [A case of interstitial lung disease associated with gemcitabine treatment in a patient with locally advanced pancreatic cancer following proton beam radiother… Co-author PMID 23268009↗

Closest collaborators

The 25 strongest of 83 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hirochika Toyama · 34 shared papers, 2011–2026 · strength 4.66
  2. Hiroaki Yanagimoto · 19 shared papers, 2015–2026 · strength 2.69
  3. Yoshihide Nanno · 14 shared papers, 2014–2026 · strength 2.54
  4. Jun Ishida · 15 shared papers, 2013–2026 · strength 2.44
  5. Sadaki Asari · 20 shared papers, 2011–2026 · strength 2.31
  6. Takuya Mizumoto · 11 shared papers, 2017–2026 · strength 2.03
  7. Atsuhiro Masuda · 13 shared papers, 2017–2026 · strength 1.66
  8. Arata Sakai · 10 shared papers, 2018–2026 · strength 1.38
  9. Masanori Gonda · 9 shared papers, 2022–2026 · strength 1.31
  10. Takashi Kobayashi · 11 shared papers, 2017–2024 · strength 1.29
  11. Keitaro Sofue · 12 shared papers, 2017–2026 · strength 1.29
  12. Dongha Lee · 5 shared papers, 2025–2026 · strength 1.27
  13. Yuzo Kodama · 9 shared papers, 2022–2024 · strength 1.27
  14. Masahiro Tsujimae · 8 shared papers, 2022–2026 · strength 1.14
  15. Kohei Yamakawa · 8 shared papers, 2022–2024 · strength 1.10
  16. Shohei Abe · 7 shared papers, 2022–2024 · strength 0.94
  17. Sachiyo Shirakawa · 10 shared papers, 2012–2023 · strength 0.94
  18. Takeshi Tanaka · 7 shared papers, 2022–2024 · strength 0.93
  19. Ippei Matsumoto · 18 shared papers, 2011–2023 · strength 0.91
  20. Yoshiyuki Harada · 6 shared papers, 2023–2026 · strength 0.90
  21. Mika Miki · 6 shared papers, 2023–2026 · strength 0.90
  22. Shigeto Masuda · 6 shared papers, 2022–2024 · strength 0.76
  23. Tomoo Itoh · 6 shared papers, 2022–2024 · strength 0.76
  24. Tomoaki Okimoto · 4 shared papers, 2019–2026 · strength 0.64
  25. Kazuki Terashima · 4 shared papers, 2019–2026 · strength 0.64

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.